Stepwise-edited, human melanoma models reveal mutations' effect on tumor and microenvironment.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
29 04 2022
Historique:
entrez: 28 4 2022
pubmed: 29 4 2022
medline: 3 5 2022
Statut: ppublish

Résumé

Establishing causal relationships between genetic alterations of human cancers and specific phenotypes of malignancy remains a challenge. We sequentially introduced mutations into healthy human melanocytes in up to five genes spanning six commonly disrupted melanoma pathways, forming nine genetically distinct cellular models of melanoma. We connected mutant melanocyte genotypes to malignant cell expression programs in vitro and in vivo, replicative immortality, malignancy, rapid tumor growth, pigmentation, metastasis, and histopathology. Mutations in malignant cells also affected tumor microenvironment composition and cell states. Our melanoma models shared genotype-associated expression programs with patient melanomas, and a deep learning model showed that these models partially recapitulated genotype-associated histopathological features as well. Thus, a progressive series of genome-edited human cancer models can causally connect genotypes carrying multiple mutations to phenotype.

Identifiants

pubmed: 35482859
doi: 10.1126/science.abi8175
pmc: PMC9427199
mid: NIHMS1829473
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabi8175

Subventions

Organisme : NCI NIH HHS
ID : R50 CA252138
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007753
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Références

Nat Rev Cancer. 2016 Jun;16(6):345-58
pubmed: 27125352
Science. 2015 Nov 13;350(6262):823-6
pubmed: 26564855
Nature. 2016 Nov 17;539(7629):384-389
pubmed: 27820943
Nat Genet. 2013 Oct;45(10):1127-33
pubmed: 24071851
Cancer. 2012 May 1;118(9):2476-85
pubmed: 21953023
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Elife. 2019 Jul 08;8:
pubmed: 31282856
Nat Cancer. 2020 Aug;1(8):789-799
pubmed: 33763651
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
J Vis Exp. 2011 Aug 03;(54):
pubmed: 21847077
Nat Rev Cancer. 2019 Jul;19(7):377-391
pubmed: 31209265
J Invest Dermatol. 2016 Dec;136(12):2342-2344
pubmed: 27884291
Sci Signal. 2013 Mar 26;6(268):pe11
pubmed: 23532332
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Nat Cell Biol. 2021 Sep;23(9):1035-1047
pubmed: 34475532
Oncotarget. 2017 Sep 14;8(49):85492-85503
pubmed: 29156735
Nat Biotechnol. 2014 Mar;32(3):267-73
pubmed: 24535568
Cell. 2016 Dec 15;167(7):1853-1866.e17
pubmed: 27984732
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Cell. 2016 Dec 15;167(7):1883-1896.e15
pubmed: 27984734
PLoS One. 2014 Mar 28;9(3):e93232
pubmed: 24681574
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Oncogene. 2013 Oct 24;32(43):5129-43
pubmed: 23416979
Nat Cancer. 2020 Jun;1(6):635-652
pubmed: 35121978
Nature. 2020 Jun;582(7812):399-404
pubmed: 32494013
Oncogene. 2014 May 8;33(19):2413-22
pubmed: 23728340
Cell Rep. 2020 May 19;31(7):107628
pubmed: 32433953
Cancer Cell. 2018 Jul 9;34(1):45-55.e4
pubmed: 29990500
Br J Cancer. 2016 Nov 22;115(11):1273-1279
pubmed: 27764844
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000
pubmed: 26286987
Oncotarget. 2015 May 20;6(14):12297-309
pubmed: 25909218
Nature. 2019 Feb;566(7742):73-78
pubmed: 30728521
Nat Genet. 2020 Nov;52(11):1208-1218
pubmed: 33128048
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nature. 2009 Apr 9;458(7239):719-24
pubmed: 19360079
Cancer Cell. 2018 Jul 9;34(1):56-68.e9
pubmed: 29990501
Pigment Cell Melanoma Res. 2016 Mar;29(2):122-40
pubmed: 26386262
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Nature. 2015 May 7;521(7550):43-7
pubmed: 25924068
Annu Rev Pathol. 2014;9:239-71
pubmed: 24460190
Anal Cell Pathol (Amst). 2019 Dec 16;2019:3851576
pubmed: 31934531
Nat Rev Cancer. 2009 Apr;9(4):274-84
pubmed: 19308067
J Clin Invest. 1999 May;103(9):1269-76
pubmed: 10225970
Nat Commun. 2017 Sep 21;8(1):644
pubmed: 28935960
Cell. 2013 Mar 28;153(1):17-37
pubmed: 23540688
Nat Commun. 2020 Aug 27;11(1):4296
pubmed: 32855387
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Cancer Cell. 2011 Dec 13;20(6):741-54
pubmed: 22172720
Cancer Cell. 2021 May 10;39(5):610-631
pubmed: 33545064
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
Nat Genet. 2012 Sep;44(9):1006-14
pubmed: 22842228
Genome Biol. 2018 Dec 19;19(1):224
pubmed: 30567574
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Nature. 2005 Jul 7;436(7047):117-22
pubmed: 16001072
Nat Biotechnol. 2015 Sep;33(9):985-989
pubmed: 26121415
Nat Cancer. 2020 Aug;1(8):800-810
pubmed: 35122049
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
Cell. 2014 Oct 23;159(3):647-61
pubmed: 25307932
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389859
Science. 2013 Feb 15;339(6121):823-6
pubmed: 23287722
Oncogene. 2013 Sep 5;32(36):4203-13
pubmed: 23045275
J Invest Dermatol. 2016 Dec;136(12):2502-2505
pubmed: 27345472
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Cell Cycle. 2007 Feb 15;6(4):394-6
pubmed: 17329971
Eur J Cancer. 2013 Apr;49(6):1297-304
pubmed: 23290787
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Oncogene. 2013 Apr 25;32(17):2230-8
pubmed: 22665063
Nat Med. 2015 Mar;21(3):256-62
pubmed: 25706875
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Eur J Cancer. 2015 Dec;51(18):2792-9
pubmed: 26608120

Auteurs

Eran Hodis (E)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115, USA.

Elena Torlai Triglia (E)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

John Y H Kwon (JYH)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Tommaso Biancalani (T)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Labib R Zakka (LR)

Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Harvard Medical School, Boston, MA 02115, USA.

Saurabh Parkar (S)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Jan-Christian Hütter (JC)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Lorenzo Buffoni (L)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Toni M Delorey (TM)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Devan Phillips (D)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Danielle Dionne (D)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Lan T Nguyen (LT)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Denis Schapiro (D)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.

Zoltan Maliga (Z)

Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.

Connor A Jacobson (CA)

Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.

Ayal Hendel (A)

The Mina and Everard Goodman Faculty of Life Sciences and Advanced Materials and Nanotechnology Institute, Bar-Ilan University, Ramat-Gan 52900, Israel.

Orit Rozenblatt-Rosen (O)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Martin C Mihm (MC)

Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Harvard Medical School, Boston, MA 02115, USA.

Levi A Garraway (LA)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Aviv Regev (A)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA 02139, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH